Genetic detoxification of an aroA Salmonella enterica serovar Typhimurium vaccine strain does not compromise protection against virulent Salmonella and enhances the immune responses towards a protective malarial antigen

FEMS Immunology and Medical Microbiology

Volumn 52, Issue 2, 2008, Pages 237-246

  McKelvie, Nicola D ^a,b   Khan, Shahid A ^c,e   Karavolos, Michail H ^a   Bulmer, David M ^a   Lee, Jeong Jin ^a,d   DeMarco, Raquel ^a   Maskell, Duncan J ^e   Zavala, Fidel ^f   Hormaeche, Carlos E ^a   Anjam Khan, C M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Constella Group Ltd ^*  (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d LG Chemical Ltd   (South Korea)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

aroA; Lipopolysaccharide; Multivalent vaccine; Salmonella; waaN

Indexed keywords

ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; CIRCUMSPOROZOITE PROTEIN; CYTOKINE; GENE PRODUCT; LIPID A; MYRISTYL TRANSFERASE; SALMONELLOSIS VACCINE; TETANUS TOXIN; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AROA GENE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; DETOXIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SEROTYPE; WAAN GENE; WILD TYPE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, PROTOZOAN; BACTERIAL PROTEINS; CELL LINE; COLONY COUNT, MICROBIAL; FEMALE; LIPOPOLYSACCHARIDES; LIVER; MACROPHAGES; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; POLYSACCHARIDES, BACTERIAL; PROTOZOAN PROTEINS; SALMONELLA INFECTIONS; SALMONELLA TYPHIMURIUM; SALMONELLA VACCINES; SPLEEN; TETANUS TOXIN; TUMOR NECROSIS FACTOR-ALPHA; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED;

EID: 39049107050     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00368.x     Document Type: Article

References (37)

1. Clairmont C, Lee KC, Pike J et al 2000) Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 181 : 1996 2002.
2. Cunningham C Nemunaitis J (2001) A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001. Human Gene Ther 12 : 1594 1596.
3. Dilts DA, Riesenfeld-Orn I, Fulginiti JP et al 2000) Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 18 : 1473 1484.
4. Dunstan SJ, Simmons CP Strugnell RA (1999) Use of in vivo-regulated promoters to deliver antigens from attenuated Salmonella enterica var. Typhimurium. Infect Immun JID - 0246127 67 : 5133 5141.
5. Engel H, Smink AJ, van Wijngaarden L Keck W (1992) Murein-metabolizing enzymes from Escherichia coli: existence of a second lytic transglycosylase. J Bacteriol 174 : 6394 6403.
6. Fadl AA, Sha J, Klimpel GR, Olano JP, Galindo CL Chopra AK (2005) Attenuation of Salmonella enterica serovar Typhimurium by altering biological functions of murein lipoprotein and lipopolysaccharide. Infect Immun 73 : 8433 8436.
7. Giron JA, Xu JG, Gonzalez CR, Hone D, Kaper JB Levine MM (1995) Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by delta aroC, delta aroD Salmonella typhi vaccine strain CVD 908. Vaccine 13 : 939 946.
8. Gonzalez C, Hone D, Noriega FR, Tacket CO, Davis JR, Losonsky G, Nataro JP, Hoffman S, Malik A Nardin E (1994) Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J Infect Dis 169 : 927 931.
9. Harrison JA, Villarreal-Ramos B, Mastroeni P, Demarco DH Hormaeche CE (1997) Correlates of protection induced by live Aro-Salmonella typhimurium vaccines in the murine typhoid model. Immunology 90 : 618 625.
10. Hoiseth SK Stocker BA (1981) Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291 : 238 239.
11. Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G Levine MM (1992) Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine. J Clin Invest 90 : 412 420.
12. Hormaeche CE (1979) Natural resistance to Salmonella typhimurium in different inbred mouse strains. Immunology 37 : 311 318.
13. Hormaeche CE, Joysey HS, Desilva L, Izhar M Stocker BA (1991) Immunity conferred by Aro-Salmonella live vaccines. Microb Pathogen 10 : 149 158.
14. Hormaeche CE, Khan CM, Mastroeni P, Villarreal-Ramos B, Dougan G, Roberts M Chatfield SN (1995) Salmonella vaccines: mechanisms of immunity and their use as carriers of recombinant antigens. Molecular and Clinical Aspects of Bacterial Vaccine Development (Ala'aldeen DAA Hormaeche CE, eds), pp. 119 153. John Wiley & Sons, Chichester.
15. Kalupahana R, Emilianus AR, Maskell D Blacklaws B (2003) Salmonella enterica serovar Typhimurium expressing mutant lipid A with decreased endotoxicity causes maturation of murine dendritic cells. Infect Immun 71 : 6132 6140.
16. Khan CM, Villarreal-Ramos B, Pierce RJ et al 1994a) Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. Proc Natl Acad Sci USA 91 : 11261 11265.
17. Khan CM, Villarreal-Ramos B, Pierce RJ, Demarco de Hormaeche R, McNeill H, Ali T, Chatfield S, Capron A, Dougan G Hormaeche CE (1994b) Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella. J Immunol 153 : 5634 5642.
18. Khan SA, Everest P, Servos S, Foxwell N, Zahringer U, Brade H, Rietschel ET, Dougan G, Charles IG Maskell DJ (1998) A lethal role for lipid A in Salmonella infections. Mol Microbiol 29 : 571 579.
19. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 : 680 685.
20. Lee JJ, Sinha KA, Harrison JA, de Hormaeche RD, Riveau G, Pierce RJ, Capron A, Wilson RA Khan CMA (2000) Tetanus toxin fragment C expressed in live Salmonella vaccines enhances antibody responses to its fusion partner Schistosoma haematobium glutathione S-transferase. Infect Immun 68 : 2503 2512.
21. Levine MM, Herrington D, Murphy JR, Morris JG, Losonsky G, Tall B, Lindberg AA, Svenson S, Baqar S Edwards MF (1987) Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest 79 : 888 902.
22. Low KB, Ittensohn M, Le T et al 1999) Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo. [see comment]. Nature Biotechnol 17 : 37 41.
23. McKelvie ND, Stratford S, Wu T et al 2004) Expression of heterologous antigens in Salmonella typhimurium vaccine vectors using the in vivo-inducible, SPI-2 promoter, ssaG. Vaccine 22 : 3243 3255.
24. Oxer MD, Bentley CM, Doyle JG, Peakman TC, Charles IG Makoff AJ (1991) High level heterologous expression in E. coli using the anaerobically-activated nirB promoter. Nucleic Acids Res 19 : 2889 2892.
25. Reed LJ Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27 : 493 497.
26. Roberts M, Chatfield S, Pickard D, Li J Bacon A (2000) Comparison of abilities of Salmonella enterica serovar Typhimurium aroA aroD and aroA htrA mutants to act as live vectors. Infect Immun 68 : 6041 6043.
27. Rosenberg SA, Spiess PJ Kleiner DE (2002) Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 25 : 218 225.
28. Shata MT, Stevceva L, Agwale S, Lewis GK Hone DM (2000) Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 6 : 66 71.
29. Sigwart DF, Stocker BA Clements JD (1989) Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect Immun 57 : 1858 1861.
30. Sinha K, Mastroeni P, Harrison J, de Hormaeche RD Hormaeche CE (1997) Salmonella typhimurium aroA, htrA, and aroD htrA mutants cause progressive infections in athymic (nu/nu) BALB/c mice. Infect Immun 65 : 1566 1569.
31. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R Levine MM (1992) Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 10 : 443 446.
32. Tacket CO, Galen J, Sztein MB et al 2000) Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol 97 : 146 153.
33. Toso JF, Gill VJ, Hwu P et al 2002) Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 20 : 142 152.
34. Tsai CM Frasch CE (1982) A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 119 : 119.
35. VanCott JL, Chatfield SN, Roberts M, Hone DM, Hohmann EL, Pascual DW, Yamamoto M, Kiyono H McGhee JR (1998) Regulation of host immune responses by modification of Salmonella virulence genes. Nat Med 4 : 1247 1252.
36. Westphal O Jann K (1965) Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 234 : 1945 1950.
37. WHO (2000) Typhoid vaccines. Wkly Epidemiol Rec 75 : 257 264.